Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2013, Article ID 183061, 5 pages
http://dx.doi.org/10.1155/2013/183061
Review Article

Curbing Inflammation in the Ischemic Heart Disease

Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo, Avenida Bandeirantes 3900, 14048-900 Ribeirão Preto, SP, Brazil

Received 13 February 2013; Accepted 14 May 2013

Academic Editor: Robert Clive Landis

Copyright © 2013 Paulo Roberto B. Evora et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Boltax and E. E. Fischel, “Serologic tests for inflammation; serum complement, c-reactive protein and erythrocyte sedimentation rate in myocardial infarction,” The American Journal of Medicine, vol. 20, no. 3, pp. 418–427, 1956. View at Google Scholar · View at Scopus
  2. G. Lofstrom, “Non-specific capsular swelling in pneumococci,” Acta Medica Scandinavica, supplement 141, 1943. View at Google Scholar
  3. I. G. Kroop and N. H. Shackman, “Level of C-reactive protein as a measure of acute myocardial infarction,” Proceedings of the Society for Experimental Biology and Medicine, vol. 86, no. 1, pp. 95–97, 1954. View at Google Scholar · View at Scopus
  4. S. K. Elster, E. L. Levinger, and H. Levy, “Study ot C-reactive protein in the sera of patients with acute myocardial infarction,” Chinese Research Proceedings, vol. 3, p. 112, 1955. View at Google Scholar
  5. M. Suzuki, “Acute coronary syndromes as auto-inflammatory disorders,” Current Pharmacology Design, vol. 18, pp. 4370–4384, 2012. View at Google Scholar
  6. L. M. Biasucci, G. Liuzzo, D. J. Angiolillo, G. Sperti, and A. Maseri, “Inflammation and acute coronary syndromes,” Herz, vol. 25, no. 2, pp. 108–112, 2000. View at Google Scholar · View at Scopus
  7. X. Cheng, Y. Liao, H. Ge et al., “Th1/Th2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation,” Journal of Clinical Immunology, vol. 25, no. 3, pp. 246–253, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. R. G. Kilbourn, D. L. Traber, and C. Szabo, “Nitric oxide and shock,” Disease-a-Month, vol. 43, no. 5, pp. 282–348, 1997. View at Google Scholar · View at Scopus
  9. H. R. Reynolds and J. S. Hochman, “Cardiogenic shock current concepts and improving outcomes,” Circulation, vol. 117, no. 5, pp. 686–697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. L. G. Howes and D. G. Brillante, “Expert opinion on Tilarginine in the treatment of shock,” Expert Opinion on Investigational Drugs, vol. 17, no. 10, pp. 1573–1580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Kaluski, N. Uriel, O. Milo-Cotter, and M. Klapholz, “Nitric oxide synthase inhibitors in cardiogenic shock: present and future,” Future Cardiology, vol. 4, no. 2, pp. 183–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. S. Hochman, J. H. Alexander, H. R. Reynolds et al., “Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial,” Journal of the American Medical Association, vol. 297, no. 15, pp. 1657–1666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Bailey, T. W. Pope, S. A. Moore, and C. L. Campbell, “The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here?” American Journal of Cardiovascular Drugs, vol. 7, no. 5, pp. 337–345, 2007. View at Google Scholar · View at Scopus
  14. P. R. B. Evora, P. J. F. Ribeiro, J. Carlos, S. De Andrade, and K. M. Taylor, “Methylene blue administration in SIRS after cardiac operations,” Annals of Thoracic Surgery, vol. 63, no. 4, pp. 1212–1213, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. P. R. B. Evora, P. J. D. F. Ribeiro, V. D. A. Vicente et al., “Methylene blue for vasoplegic syndrome treatment in heart surgery. Fifteen years of questions, answers, doubts and certainties,” Brazilian Journal of Cardiovascular Surgery, vol. 24, no. 3, pp. 279–288, 2009. View at Google Scholar · View at Scopus
  16. S. Lin, H. Yokoyama, V. E. Rac, and S. C. Brooks, “Novel biomarkers in diagnosing cardiac ischemia in the emergency department: a systematic review,” Resuscitation, vol. 83, no. 6, pp. 684–691, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. W. Sels, E. H. Elsenberg, I. E. Hoefer et al., “Fractional flow reserve is not associated with inflammatory markers in patients with stable coronary artery disease,” PLoS ONE, vol. 7, Article ID e46356, 2012. View at Google Scholar
  18. R. Klingenberg and T. F. Luscher, “Inflammation in coronary artery disease and acute myocardial infarction—is the stage set for novel therapies?” Current Pharmacology Design, vol. 18, pp. 4358–4369, 2012. View at Google Scholar
  19. R. D. Bona, G. Liuzzo, D. Pedicino et al., “Anti-inflammatory treatment of acute coronary syndromes,” Current Pharmacology Design, vol. 17, pp. 4172–4189, 2011. View at Google Scholar
  20. L. Timmers, G. Pasterkamp, V. C. De Hoog, F. Arslan, Y. Appelman, and D. P. V. De Kleijn, “The innate immune response in reperfused myocardium,” Cardiovascular Research, vol. 94, no. 2, pp. 276–283, 2012. View at Publisher · View at Google Scholar · View at Scopus